Our data are comparable to those of Maron et al,35 who showed a 58% (four of seven) objective response rate among patients with EGFR-amplified gastric cancer (all seven patients were positive for EGFR amplification by tissue NGS, and six were positive by cfDNA analysis). The gene discussed is EGFR; the disease is gastric cancer.